Mu and delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain—coupling with adenylate cyclase, localisation on the same neurones and association with dopamine (D1) receptor adenylate cyclase

1991 ◽  
Vol 30 (11) ◽  
pp. 1233-1239 ◽  
Author(s):  
P Eriksson
Keyword(s):  
Adenylate Cyclase ◽  
Primary Cultures ◽  
Opiate Receptors ◽  
Dopamine D1 Receptor ◽  
D1 Receptor ◽  
The Brain

scholarly journals The Signaling and Pharmacology of the Dopamine D1 Receptor

2022 ◽  
Vol 15 ◽  
Author(s):  
Jace Jones-Tabah ◽  
Hanan Mohammad ◽  
Emma G. Paulus ◽  
Paul B. S. Clarke ◽  
Terence E. Hébert
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Neuronal Excitability ◽  
Motor Behavior ◽  
Motor Impairment ◽  
Dopamine D1 Receptor ◽  
D1 Receptor ◽  
Target Cells ◽  
The Brain

The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive processes. Although the D1R was initially identified as a promising drug target almost 40 years ago, the development of clinically useful ligands has until recently been hampered by a lack of suitable candidate molecules. The emergence of new non-catechol D1R agonists, biased agonists, and allosteric modulators has renewed clinical interest in drugs targeting this receptor, specifically for the treatment of motor impairment in Parkinson's Disease, and cognitive impairment in neuropsychiatric disorders. To develop better therapeutics, advances in ligand chemistry must be matched by an expanded understanding of D1R signaling across cell populations in the brain, and in disease states. Depending on the brain region, the D1R couples primarily to either Gαs or Gαolf through which it activates a cAMP/PKA-dependent signaling cascade that can regulate neuronal excitability, stimulate gene expression, and facilitate synaptic plasticity. However, like many GPCRs, the D1R can signal through multiple downstream pathways, and specific signaling signatures may differ between cell types or be altered in disease. To guide development of improved D1R ligands, it is important to understand how signaling unfolds in specific target cells, and how this signaling affects circuit function and behavior. In this review, we provide a summary of D1R-directed signaling in various neuronal populations and describe how specific pathways have been linked to physiological and behavioral outcomes. In addition, we address the current state of D1R drug development, including the pharmacology of newly developed non-catecholamine ligands, and discuss the potential utility of D1R-agonists in Parkinson's Disease and cognitive impairment.

Effects of repeated methamphetamine administration on dopamine D1 receptor, D2 receptor and adenylate cyclase type V mRNA levels in the rat striatum

1997 ◽  
Vol 222 (3) ◽  
pp. 175-178 ◽  
Author(s):  
Toshiaki Shishido ◽  
Yoshinori Watanabe ◽  
Hiroki Suzuki ◽  
Kozo Kato ◽  
Shin-Ichi Niwa ◽  
...  
Keyword(s):  
Adenylate Cyclase ◽  
D2 Receptor ◽  
Dopamine D1 Receptor ◽  
D1 Receptor ◽  
Rat Striatum ◽  
Mrna Levels ◽  
Type V

The affinity to the brain dopamine D1 receptor in vitro of triprenyl phenols isolated from the fruit bodies of Albatrellus ovinus

1997 ◽  
Vol 32 (4) ◽  
pp. 351-356 ◽  
Author(s):  
K Dekermendjian ◽  
R Shan ◽  
M Nielsen ◽  
M Stadler ◽  
O Sterner ◽  
...  
Keyword(s):  
Dopamine D1 Receptor ◽  
D1 Receptor ◽  
Brain Dopamine ◽  
The Brain
Sign in / Sign up

Export Citation Format

Share Document